TransMedics Group (TMDX) – Research Analysts’ Recent Ratings Changes

Posted by on Nov 11th, 2026

TransMedics Group (NASDAQ: TMDX) recently received a number of ratings updates from brokerages and research firms:

  • 11/9/2026 – TransMedics Group had its price target raised by UBS Group from $77.00 to $88.00. They now have a “neutral” rating on the stock.
  • 11/7/2026 – TransMedics Group was upgraded by Wall Street Zen from “sell” to “hold”.
  • 11/6/2026 – TransMedics Group had its price target raised by Canaccord Genuity Group from $95.00 to $120.00. They now have a “buy” rating on the stock.
  • 11/6/2026 – TransMedics Group had its price target raised by JPMorgan Chase & Co. from $73.00 to $85.00. They now have a “neutral” rating on the stock.
  • 11/6/2026 – TransMedics Group had its price target raised by Needham & Company LLC from $106.00 to $110.00. They now have a “buy” rating on the stock.
  • 11/2/2026 – TransMedics Group was upgraded by Zacks Research from “strong sell” to “hold”.
  • 10/13/2026 – TransMedics Group had its price target lowered by Canaccord Genuity Group from $95.00 to $94.00. They now have a “buy” rating on the stock.
  • 10/7/2026 – TransMedics Group is now covered by Barclays. They set an “overweight” rating and a $120.00 price target on the stock.

TransMedics Group Stock Down 3.0%

NASDAQ TMDX opened at $90.94 on Wednesday. The business has a fifty day moving average price of $79.84 and a 200 day moving average price of $92.74. TransMedics Group, Inc. has a one year low of $60.10 and a one year high of $156.00. The company has a debt-to-equity ratio of 1.46, a quick ratio of 4.15 and a current ratio of 4.53. The company has a market cap of $3.16 billion, a P/E ratio of 24.64, a P/E/G ratio of 1.75 and a beta of 2.14.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.21. The company had revenue of $203.01 million for the quarter, compared to analysts’ expectations of $178.06 million. TransMedics Group had a net margin of 19.85% and a return on equity of 13.30%. The firm’s quarterly revenue was up 41.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.66 EPS. Research analysts anticipate that TransMedics Group, Inc. will post 1.58 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In related news, Director David Weill purchased 1,336 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was acquired at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the transaction, the director directly owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.90% of the company’s stock.

TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.

Read More

Receive News & Ratings for TransMedics Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.